The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Nanotechnology-Based Strategies for siRNA Brain Delivery for Disease Therapy
Abstract
Small interfering RNA (siRNA)-based gene silencing technology has demonstrated significant potential for treating brain-associated diseases. However, effective and safe systemic delivery of siRNA into the brain remains challenging because of biological barriers such as enzymatic degradation, short circulation lifetime, the blood-brain barrier (BBB), insufficient tissue penetration, cell endocytosis, and cytosolic transport. Nanotechnology offers intriguing potential for addressing these challenges in siRNA brain delivery in conjunction with chemical and biological modification strategies. In this review, we outline the challenges of systemic delivery of siRNA-based therapy for brain diseases, highlight recent advances in the development and engineering of siRNA nanomedicines for various brain diseases, and discuss our perspectives on this exciting research field for siRNA-based therapy towards more effective brain disease therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While RNAi holds great promise for treating genetic associated neurological disorders, efficient delivery of siRNA into the brain is still a remarkable obstacle to the clinical applications.[99–101]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [100]
Citations
Cites
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Self-citationNanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Nanoparticle biointerfacing by platelet membrane cloaking
Hu, C. J., Fang, R. H., Wang, K.-C., Luk, B. T., Thamphiwatana, S., Dehaini, D., Nguyen, P., Angsantikul, P., Wen, C. H., Kroll, A. V., et al. (2015) · Nature · doi:10.1038/nature15373 · Cited by 1,795
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. P. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,271
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Cited by
Sorted by citations
Ouyang, J., Xie, A., Zhou, J. M., Liu, R., Wang, L., Liu, H., Kong, N., & Tao, W. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01148k · Cited by 389
Self-citationAdvanced drug delivery applications of layered double hydroxide
Shirin, V. K. A., Sankar, R., Johnson, A. P., Gangadharappa, H. V., & Pramod, K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.041 · Cited by 319
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 304
Self-citationSystemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy
Gregory, J. V., Kadiyala, P., Doherty, R., Cadena, M., Habeel, S., Ruoslahti, E., Lowenstein, P. R., Castro, M. G., & Lahann, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19225-7 · Cited by 295
Wang, G., Zhao, X., Wu, H., Lovejoy, D. B., Zheng, M., Lee, A., Fu, L., Miao, K., An, Y., Sayyadi, N., et al. (2020) · Small · doi:10.1002/smll.202003654 · Cited by 236
Self-citation
Metadata
- Authors
- Zheng, M., Tao, W., Zou, Y., Farokhzad, O. C., & Shi, B.
- Affiliations
- Henan University (CN)
- Brigham and Women's Hospital (US)
- Corresponding author
- Shi, Bingyang
- Venue
- Trends in biotechnology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 36
- Issue
- 5
- Pages
- 562-575
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W2787845337
- Cited by
- 210
- References
- 84
- Citations by year
- 2026: 15 · 2025: 31 · 2024: 34 · 2023: 22 · 2022: 32 · 2021: 23 · 2020: 24 · 2019: 23 · 2018: 5
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Trends in biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (31640027, 31600809, U1604177)
- Program of China 1000-Talents Plan
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- siRNA delivery, brain drug delivery, blood-brain barrier, gene silencing, brain disorders, systemic drug delivery, chemical modification, biological modification, nanocarriers, endocytosis
- MeSH terms
- Animals, Brain Diseases, Disease Models, Animal, Humans, Drug Delivery Systems, RNA, Small Interfering, Nanostructures, Nanomedicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
